Lv61
2930 积分 2023-03-10 加入
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
36分钟前
待确认
ABS0364 SAFETY AND EFFICACY OF T CELL ENGAGER THERAPY IN PATIENTS WITH REFRACTORY AUTOIMMUNE DISEASE
6小时前
已关闭
Opportunities and limitations of B cell depletion approaches in SLE
7小时前
已完结
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
15天前
已完结
A small molecule–kinase interaction map for clinical kinase inhibitors
15天前
已完结
MKK4 inhibitor: the hope for liver failure prevention and potential small liver graft transplantation
15天前
已完结
A quantitative analysis of kinase inhibitor selectivity
15天前
已完结
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
18天前
已完结
Vemurafenib: the first drug approved for BRAF-mutant cancer
18天前
已完结
Bispecific T cell engager therapy for refractory rheumatoid arthritis
25天前
已完结
皖公网安备34019202002308
